Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone

Journal of Neurology

Volumn 252, Issue 10, 2005, Pages 1217-1222

  Goffette, Sophie ^a   Van Pesch, Vincent ^a   Vanoverschelde, Jean Louis ^a   Morandini, Emmanuel ^b   Sindic, Christian J M ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Centre Hospitalier de l'Ardenne   (Belgium)

Author keywords

Late cardiotoxicity; Long term follow up; Mitoxantrone; Multiple sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE; MITOXANTRONE;

ADULT; ANAMNESIS; ARTICLE; CARDIOTOXICITY; CLINICAL FEATURE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CONVALESCENCE; DISABILITY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOKINESIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY; TREATMENT OUTCOME; TRICUSPID VALVE REGURGITATION;

ADULT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 26644447135     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-0839-3     Document Type: Article

References (32)

1. Posner LE, Dukart G, Goldberg J, et al. (1985) Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 3:123-132
2. Gonsette RE, Demonty L (1990) Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for two years in 22 patients. Neurology 40(Suppl 1):261. Abstract. (537 P)
3. Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H (1992) Treatment of Multiple Sclerosis with Mitoxantrone. Eur Arch Psychiatry Clin Neurosci 242:96-102
4. Kappos L, Gold R, Kündtier E, et al. (1990) Mitoxantrone in the treatment of rapidly progressive MS: a pilot study with serial gadolinium-enhanced MRI. Neurology 40(Suppl 1): 261. Abstract. (539 P)
5. Noseworthy JH, Hopkins MB, Vandervoort MK, et al. (1993) An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 43:1401-1406
6. Millefiorini E, Gasperini C, Pozzilli C, et al. (1997) Randomized placebo-controlled trial mitoxantrone in relapsing-remitting multiple sclerosis: a 24-month clinical and MRI outcome. J Neurol 244:153-159
7. Edan G, Miller D, Clanet M, et al. (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112-118
8. van de Wyngaert FA, Beguin C, D'Hooghe MB, et al. (2001) A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg 101:210-216
9. Hartung HP, Gonsette R, König N, et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360:2018-2025
10. Gonsette RE (1996) Mitoxantrone immunotherapy in multiple sclerosis. Mult Scler 1:329-332
11. Edan G, Brochet B, Clanet M, et al. (2004) Safety profile of mitoxantrone in a cohort of 802 MS patients. A for year follow-up study. Neurology 62(Suppl 5): P 06093 Abstract
12. Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents. Drug Safety 22:263-302
13. Unverferth DV, Unfervert BJ, Balcerzak SP, Bashore TA, Neidhart JA (1983) Cardiac evaluation of mitoxantrone. Cancer Treat Rep 67:343-350
14. Keefe DL (2001) Anthracycline-induced cardiomyopathy. Semin Oncol 28(4 Suppl 12):2-7
15. Herman EH, Zhang J, Hasinoff BB, Clark JR, Ferrans VJ (1997) Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe (III)-mitoxantrone complex. J Mol Cell Cardiol 29:2415-2430
16. Andersson BS, Eksborg S, Vidal RF, Sundberg M, Carlberg M (1999) Anthraquinone-induced cell injury: acute toxicity of carminomycin, epirubicin, idarubicin and mitoxantrone in isolated cardiomyocytes. Toxicology 135:11-20
17. Gonsette RE (2003) Mitoxantrone in progressive multiple sclerosis: when and how to treat? J Neurol Sci 206:203-208
18. Steinherz LJ, Steinherz PG, Mangiacasale D, et al. (1981) Cardiac changes with cyclophosphamide. Med Pediatr Oncol 9:417-422
19. Cazin B, Gorin NC, Laporte JP, et al. (1986) Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 57:2061-2069
20. Feuillet L, Guedj E, Eusibio A, et al. (2003) Insuffisance cardiaque aiguë chez une patiente traitée par mitoxantrone pour sclérose en plaques. Rev Neurol (Paris) 159:1169-1172
21. McDougall AJ, McLeod JG (2003) Autonomic nervous system function in multiple sclerosis. J Neurol Sci 215:79-85
22. Olindo S, Guillon B, Helias J, Phillibert B, Magne C, Fève JR (2002) Decrease in heart ventricular ejection fraction during multiple sclerosis. Eur J Neurol 9:287-291
23. Beer M, Sandstede J, Weilbach F, et al. (2001) Cardiac metabolism and function in patients with multiple sclerosis: a combined 31P-MR-spectroscopy and MRI study. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 173:399-404
24. Mauch E, Eisenmann S, Hahn A (1999) Mitoxantrone in the treatment of patients with multiple sclerosis(MS): a large single-center experience. Mult Scler 5(Suppl 1): S94; P 366
25. Ghalie RG, Edan G, Laurent M, et al. (2002) Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 59:909-913
26. The Euro Heart Failure Survey Programme (2003) A survey on the quality of care among patients with heart failure in Europe. Eur Heart J 24:422-474
27. Aviles A, Arevila N, Diaz Maqueo JC, Gomez T, Garcia R, Jesus Nambo MA (1993) Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. Leuk Lymphoma 11:275-279
28. Ritchie JL, Singer JW, Thorning D, Sorensen SG, Hamilton GW (1980) Anthracycline cardiotoxicity: clinical and pathological outcomes assessed by radionuclide ejection fraction. Cancer 46:1109
29. Avasarala JR, Cross AH, Clifford DB, Singer BA, Siegel BA, Abbey EE (2003) Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 9:59-62
30. De Castro S, Cartoni D, Millefiorini E, et al. (1995) Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing-remitting multiple sclerosis. J Clin Pharmacol 35:627-632
31. Villani F, Galimberti M, Crippa F (1989) Evaluation of ventricular function by echography and radionuclide angiography in patients treated with mitoxantrone. Drugs Exp Clin Res 15:501-506
32. Strotmann JM, Spindler M, Weilbach FX, Gold R, Ertl G, Voelker W (2002) Myocardial function in patients with multiple sclerosis treated with low-dose mitoxantrone. Am J Cardiol 89:1222-1225